All the news Showing 10 of 40 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients Liz Highleyman / 05 February 2015 People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – ... Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus Liz Highleyman / 04 February 2015 A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at the American Association for ... Tenofovir continues to suppress hepatitis B virus for eight years Keith Alcorn / 05 December 2014 Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver ... Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure Liz Highleyman / 28 November 2013 A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced treatment failure with ... Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk Liz Highleyman / 11 November 2013 Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma, according to findings presented last week at The Liver Meeting 2013, the 64th annual meeting ... Entecavir and tenofovir both work well against hepatitis B in clinical practice Liz Highleyman / 25 October 2013 Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus (HBV) in a Turkish study presented at the IDWeek 2013 conference held recently in San Francisco. Entecavir appeared to have an ... Many people need hepatitis B treatment in the Gambia Liz Highleyman / 17 July 2013 About 8% of people tested through a community-based screening program in the Gambia have hepatitis B, and about 8% of these have advanced liver disease and meet European criteria for antiviral therapy, according ... Truvada works best for immune-tolerant hepatitis B patients, but do they need treatment? Liz Highleyman / 07 May 2013 A combination of tenofovir and emtricitabine (the drugs in the combination pill Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over four years for people with inactive or immune-tolerant disease, ... Nucleoside analogues reduce hepatitis B liver cancer risk Liz Highleyman / 29 November 2012 Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection surgery, according to data presented ... Tenofovir safe and effective for long-term hepatitis B treatment with little bone loss Liz Highleyman / 22 November 2012 Tenofovir (Viread) continues to be safe and effective for treating chronic hepatitis B through eight years of follow-up, researchers reported at The Liver Meeting 2012, the 63rd Annual Meeting of the American Association ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive